<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430065</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK02</org_study_id>
    <nct_id>NCT01430065</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open Label, Single Sequence, Drug Interaction Study of the Pharmacokinetics of ASP015K and Tacrolimus After Separate and Concomitant Administration to Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study characterizes the pharmacokinetic effects of ASP015K on Tacrolimus in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects will be confined to the unit for 13 days and have a brief follow-up visit to&#xD;
      obtain hematology blood samples. Numerous blood and urine samples will be taken to determine&#xD;
      the pharmacokinetics of the drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic assessment of AUC through the analysis of blood and urine samples</measure>
    <time_frame>Up to Day 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment of maximum concentration (Cmax) through the analysis of blood and urine samples</measure>
    <time_frame>Up to Day 13</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics of ASP015K</condition>
  <condition>Drug Interactions</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Tacrolimus and ASP015K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>oral</description>
    <arm_group_label>Tacrolimus and ASP015K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>Tacrolimus and ASP015K</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  If female, the subject is at least 2 years post menopausal or is surgically sterile&#xD;
             per documentation provided by a third party medical professional and the subject is&#xD;
             not pregnant as documented by a negative serum pregnancy test&#xD;
&#xD;
          -  If male, the subject agrees to sexual abstinence and/or to use a highly effective&#xD;
             method of birth control during the study period&#xD;
&#xD;
          -  Subject is medically healthy, with no clinically significant medical history or&#xD;
             abnormalities observed upon physical examination or 12-lead electrocardiogram (ECG)&#xD;
&#xD;
          -  Subjects must weigh at least 45 kg and have a body mass index (BMI) of 18-32 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a history of chronic diarrhea&#xD;
&#xD;
          -  Subject has been vaccinated within the last 60 days prior to study drug administration&#xD;
&#xD;
          -  The subject has a previous history of any clinically significant neurological,&#xD;
             gastro-intestinal, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric,&#xD;
             endocrine, hematological disorder or disease&#xD;
&#xD;
          -  Subject has a positive test for hepatitis C antibody, or positive for hepatitis B&#xD;
             surface antigen (HBsAg)&#xD;
&#xD;
          -  Subject has a history of the human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  The subject has an absolute neutrophil count (ANC) &lt; 2500 cells/mm3 Subject has had&#xD;
             clinically significant illness within 1 month prior to study drug administration&#xD;
&#xD;
          -  Subject has a recent history (within the last 6 months) of drug or alcohol abuse or a&#xD;
             positive urine screen for alcohol or drugs of abuse/illegal drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transplant</keyword>
  <keyword>ASP015K</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

